Abcellera Biologics Inc (ABCL) — Cash Flow Quality Index
Abcellera Biologics Inc (ABCL) has a Cash Flow Quality Index of -4.76x as of September 2022. Operating cash flow of $-126.79 Million is below net income of $26.62 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Abcellera Biologics Inc operating cash flow efficiency to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Abcellera Biologics Inc Cash Flow Quality Index (2018–2022)
Historical Cash Flow Quality Index for Abcellera Biologics Inc across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Abcellera Biologics Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Abcellera Biologics Inc (2018–2022)
Year-by-year earnings quality comparison for Abcellera Biologics Inc. For live market cap and the full company financial profile, see ABCL company net worth.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | 1.75x | $277.36 Million | $158.52 Million | ▲ +9.8% |
| 2021 | 1.59x | $244.58 Million | $153.46 Million | ▲ +735.3% |
| 2020 | 0.19x | $22.69 Million | $118.92 Million | ▼ -98.3% |
| 2018 | 11.54x | $3.56 Million | $309.00K | — |